Publication

Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) plus AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol

Attard, G.
; 
Murphy, L.
; 
Clarke, Noel W
; 
Cross, W.
; 
Gillessen, S.
; 
Amos, C.
; 
Brawley, C.
; 
Jones, R.
; 
Pezaro, C.
; 
Malik, Z.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Attard, G.
Murphy, L.
Clarke, Noel W
Cross, W.
Gillessen, S.
Amos, C.
Brawley, C.
Jones, R.
Pezaro, C.
Malik, Z.
Montazeri, A.
Millman, R.
Cook, A.
Gilbert, D.
Langley, R.
Parker, C.
Sydes, M.
Brown, L.
Parmar, M.
James, N.
Affiliation
Research Department Of Oncology, UCL Cancer Institute - UCL - London's Global University, WC1 E6BT - London/GB
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Attard G, Murphy L, Clarke N, Cross W, Gillessen S, Amos C, et al. Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) plus AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol. Annals of Oncology. 2022 Sep;33(7):S1427-S8. PubMed PMID: WOS:000866211602475.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625987
Embedded videos